Pfizer Inc
NYSE:PFE
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.5384
31.39
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Pfizer Inc
Pfizer Inc
Revenue
Pfizer Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$60.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$87.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
Pfizer Inc
Revenue Breakdown
Breakdown by Geography
Pfizer Inc
|
Total Revenue:
58.5B
USD
|
|
United States:
27.1B
USD
|
|
Emerging Markets:
12B
USD
|
|
Developed Europe:
11.7B
USD
|
|
Developed Rest Of World:
7.8B
USD
|
Breakdown by Segments
Pfizer Inc
|
Total Revenue:
58.5B
USD
|
|
Biopharma:
57.2B
USD
|
|
Comirnaty Direct Sales And Alliance Revenues:
11.2B
USD
|
|
Eliquis Alliance Revenues And Direct Sales:
6.7B
USD
|
|
Prevnar Family:
6.4B
USD
|
|
Ibrance:
4.8B
USD
|
|
Vyndaqel Family:
3.3B
USD
|
|
All Other Specialty Care:
2.2B
USD
|
|
All Other Primary Care:
1.8B
USD
|
|
Xeljanz:
1.7B
USD
|
|
Business Innovation Segment:
1.3B
USD
|
|
Paxlovid:
1.3B
USD
|
|
Pfizer Centreone:
1.3B
USD
|
|
Xtandi Alliance Revenues:
1.2B
USD
|
|
All Other Anti-Infectives:
1.1B
USD
|
|
Inlyta:
1B
USD
|
|
Nurtec Odt/Vydura:
928m
USD
|
|
Abrysvo:
890m
USD
|
|
Enbrel (Outside The United States And Canada):
830m
USD
|
|
Sulperazon:
757m
USD
|
|
Bosulif:
645m
USD
|
|
Ig Portfolio:
584m
USD
|
|
Genotropin:
539m
USD
|
|
Lorbrena:
539m
USD
|
|
Zavicefta:
511m
USD
|
|
Inflectra:
490m
USD
|
|
All Other Oncology:
433m
USD
|
|
Benefix:
424m
USD
|
|
Zirabev:
424m
USD
|
|
Zithromax:
406m
USD
|
|
Premarin Family:
397m
USD
|
|
Ruxience:
390m
USD
|
|
Xalkori:
374m
USD
|
|
Retacrit:
340m
USD
|
|
Medrol:
339m
USD
|
|
Bmp2:
338m
USD
|
|
Oxbryta:
328m
USD
|
|
Aromasin:
301m
USD
|
|
Fsme-Immun/Ticovac:
268m
USD
|
|
Somavert:
267m
USD
|
|
Fragmin:
238m
USD
|
|
Besponsa:
236m
USD
|
|
Refacto Af/Xyntha:
230m
USD
|
|
Braftovi:
213m
USD
|
|
Cresemba:
195m
USD
|
|
Bavencio Alliance Revenues:
190m
USD
|
|
Vfend:
187m
USD
|
|
Sutent:
180m
USD
|
|
Nimenrix:
179m
USD
|
|
Mektovi:
174m
USD
|
|
Bicillin:
158m
USD
|
|
Cibinqo:
128m
USD
|
|
Trumenba:
126m
USD
|
|
Trazimera:
91m
USD
|
|
Padcev:
52m
USD
|
|
Adcetris:
46m
USD
|
|
Pfizer Ignite:
44m
USD
|
|
Tukysa:
17m
USD
|
|
Tivdak:
4m
USD
|
Pfizer Inc
Glance View
Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth. As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.
See Also
What is Pfizer Inc's Revenue?
Revenue
60.1B
USD
Based on the financial report for Sep 29, 2024, Pfizer Inc's Revenue amounts to 60.1B USD.
What is Pfizer Inc's Revenue growth rate?
Revenue CAGR 10Y
2%
Over the last year, the Revenue growth was -13%. The average annual Revenue growth rates for Pfizer Inc have been -4% over the past three years , 14% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
